1072944-86-5

Basic information

• Product Name: 5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile
• Synonyms: 5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile;5-AMINO-4-CYANO-1-(2,5-DIFLUOROPHENYL)-3-METHYLPYRAZOLE
• CAS NO: 1072944-86-5
• Molecular Formula: C11H8F2N4
• Molecular Weight: 234.2048264
• Mol File: 1072944-86-5.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile(1072944-86-5)
• EPA Substance Registry System: 5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile(1072944-86-5)

Safety Data

• Hazardous Substances Data: 1072944-86-5(Hazardous Substances Data)

Usage

Description

5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile, also known as MRTX849, is a pyrazole-based chemical compound that functions as a small molecule inhibitor of the KRAS G12C mutation. This mutation is linked to a range of cancers, and MRTX849 has demonstrated its potential as a targeted therapy by selectively binding to and inhibiting the activity of the mutant KRAS protein, thereby suppressing tumor growth. It has shown promising preclinical and clinical results and is under active research and development for the treatment of KRAS G12C-driven cancers.

Uses

Used in Oncology:
5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile is used as an oncology drug for the treatment of cancers with the KRAS G12C mutation. Its application is based on its ability to selectively target and inhibit the activity of the mutant KRAS protein, which plays a crucial role in the development and progression of these cancers.
Used in Non-Small Cell Lung Cancer Treatment:
In the field of lung cancer treatment, 5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile is used as a targeted therapy for non-small cell lung cancer patients harboring the KRAS G12C mutation. Its use is justified by its potential to directly address the molecular drivers of tumor growth in these patients, offering a more personalized approach to treatment.
Used in Colorectal Cancer Treatment:
5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile is utilized as a targeted therapeutic agent in colorectal cancer treatment, specifically for patients with the KRAS G12C mutation. Its application aims to inhibit the mutant KRAS protein, thus controlling tumor progression and potentially improving patient outcomes.
Used in Pancreatic Cancer Treatment:
Within the pancreatic cancer treatment industry, 5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile is employed as a targeted medicine for individuals with pancreatic cancer that possesses the KRAS G12C mutation. The rationale for its use lies in its capacity to interfere with the mutant KRAS protein's activity, which is implicated in the malignancy's growth and spread.
These applications highlight the potential of 5-Amino-1-(2,5-difluorophenyl)-3-methyl-1H-pyrazole-4-carbonitrile, or MRTX849, as a significant advancement in the treatment of KRAS G12C-mutated cancers, offering a more precise and effective therapeutic strategy.